25 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
1 Oct 20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
6:06am
COVID-19 pandemic. Importantly, the initial positive results seen in sepsis patients treated with AllocetraTM are consistent with those observed … -19 clinical trial. Enlivex will continue to work towards efforts aimed at combating the ongoing global COVID-19 pandemic, while continuing to execute
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Sep 21
Report of Foreign Private Issuer
6:02am
Executive Officer of Enlivex. “They also reinforce our belief that even with vaccines available, COVID-19 will migrate from a pandemic to an endemic … for, ALLOCETRATM programs, as well as potential changes in the severity level of the COVID-19 pandemic (including due to new variants of the virus
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
28 May 21
Condensed Consolidated Financial Statements
4:33pm
. However, the timelines for the Company’s clinical development programs may be extended due to direct and indirect impacts of the COVID-19 pandemic … with severe sepsis due to a lower number of pneumonic septic patients, as a result of the COVID-19 pandemic environment. As previously reported
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
due to direct and indirect impacts of the COVID-19 pandemic or new variants of the virus. For example, there has been a delay in recruiting patients … septic patients, as a result of the COVID-19 pandemic environment. As previously reported in the Company’s Annual Report on Form 20-F, the Company still
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
9 Aug 21
Enlivex Announces Second Quarter 2021 Financial Results and Provides a Business Update
8:00am
will migrate from a pandemic to an endemic, with multiple variants continuing to circulate throughout the population. Further, AllocetraTM has demonstrated … opportunities for, ALLOCETRATM programs, as well as potential changes in the severity level of the COVID-19 pandemic (including due to new variants
6-K
EX-99.1
1f15sj41r cj
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.2
ltxfy1lm 90eq
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
s936m qpz
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
z52da 3tuxry7
7 May 20
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
8:01am
6-K
EX-99.1
r0lt264k7jgc5rh3uv
16 Aug 21
Report of Foreign Private Issuer
6:12am
6-K
EX-99.1
n4znfcfsxat
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-99.1
mavzgf4p0wu7 ozlzb9
2 Aug 23
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
xw88yh9laj 4zrt
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am
6-K
EX-99.1
aaxwmsjq
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
zom 636n9zd42fisatw9
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K
EX-99.2
8pfmvqwaxk445
30 Oct 20
Condensed Consolidated Financial Statements
4:30pm
6-K/A
EX-99.2
kduu38sh wojl5qh20f
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.2
n2257kskepz2bihnd5iz
14 Aug 20
Condensed Consolidated Financial Statements
4:23pm
6-K/A
EX-99.1
ttxn2 mv0
13 Oct 20
Condensed Consolidated Financial Statements
9:16am
6-K
EX-99.1
xxo5a
3 Feb 21
Current Report
7:55am